MRKR - Marker Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Houston,
United States
Type: Equity
MRKR price evolution
MRKR
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.8 | $11.32 | $15.11 | |
| Short term investments | ||||
| Net receivables | $0.74 | $2.49 | $1.85 | $1.03 |
| Inventory | ||||
| Total current assets | $10.91 | $11.68 | $14.09 | $17.13 |
| Long term investments | ||||
| Property, plant & equipment | ||||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $10.91 | $11.68 | $14.09 | $17.13 |
| Current liabilities | ||||
| Accounts payable | $2.56 | $1.97 | $2.3 | $3.07 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $3.46 | $1.97 | $2.3 | $3.07 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $3.46 | $1.97 | $2.3 | $3.07 |
| Shareholders' equity | ||||
| Retained earnings | -$443.18 | -$440.87 | -$438.68 | -$436.29 |
| Other shareholder equity | ||||
| Total shareholder equity | $9.7 | $11.79 | $14.05 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $15.11 | $11.78 | $43.5 | $21.35 |
| Short term investments | ||||
| Net receivables | $1.03 | $2.4 | $0 | $1 |
| Inventory | ||||
| Total current assets | $17.13 | $16.62 | $45.98 | $24.41 |
| Long term investments | ||||
| Property, plant & equipment | $17.8 | $22.15 | $21.2 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $17.8 | $22.15 | $21.2 | |
| Total investments | ||||
| Total assets | $17.13 | $34.42 | $68.14 | $45.61 |
| Current liabilities | ||||
| Accounts payable | $3.07 | $2.37 | $11.13 | $6.01 |
| Deferred revenue | $2.5 | $1.15 | ||
| Short long term debt | $0.58 | $0.62 | $0.39 | |
| Total current liabilities | $3.07 | $7.78 | $12.9 | $6.4 |
| Long term debt | $7.04 | $11.25 | $11.87 | |
| Total noncurrent liabilities | $7.04 | $11.25 | $11.87 | |
| Total debt | $7.62 | $11.87 | $12.26 | |
| Total liabilities | $3.07 | $14.82 | $24.15 | $18.27 |
| Shareholders' equity | ||||
| Retained earnings | -$436.29 | -$428.05 | -$398.12 | -$356.24 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $14.05 | $19.6 | $43.99 | $27.34 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.93 | $1.17 | $1.24 | $1.06 |
| Cost of revenue | ||||
| Gross Profit | $1.17 | $1.24 | $1.06 | |
| Operating activities | ||||
| Research & development | $2.34 | $2.58 | $2.62 | |
| Selling, general & administrative | $1.14 | $1.22 | $1.38 | |
| Total operating expenses | $4.33 | $3.48 | $3.79 | $3.99 |
| Operating income | -$2.31 | -$2.55 | -$2.94 | |
| Income from continuing operations | ||||
| EBIT | -$2.19 | -$2.39 | -$2.8 | |
| Income tax expense | $0 | |||
| Interest expense | $0.09 | |||
| Net income | ||||
| Net income | -$2.31 | -$2.19 | -$2.39 | -$2.8 |
| Income (for common shares) | -$2.19 | -$2.39 | -$2.8 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.31 | $9.01 | $1.24 | $0.47 |
| Cost of revenue | ||||
| Gross Profit | $3.31 | $9.01 | $1.24 | $0.47 |
| Operating activities | ||||
| Research & development | $10.42 | $26.14 | $27.79 | $18.88 |
| Selling, general & administrative | $7.48 | $12.82 | $12.92 | $10.47 |
| Total operating expenses | $17.89 | $38.96 | $40.72 | $29.35 |
| Operating income | -$14.58 | -$29.95 | -$39.48 | -$28.89 |
| Income from continuing operations | ||||
| EBIT | -$8.23 | -$29.93 | -$41.88 | -$28.71 |
| Income tax expense | $0 | |||
| Interest expense | ||||
| Net income | ||||
| Net income | -$8.24 | -$29.93 | -$41.88 | -$28.71 |
| Income (for common shares) | -$8.24 | -$29.93 | -$41.88 | -$28.71 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$2.19 | -$2.39 | -$2.8 | |
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.06 | $0.08 | $0.14 | |
| Total cash flows from operations | -$3.57 | -$3.84 | -$2.37 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.04 | $0.05 | $0.01 | |
| Net borrowings | ||||
| Total cash flows from financing | $0.1 | $0.04 | $0.05 | $0.01 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$6.11 | -$3.52 | -$3.79 | -$2.36 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$8.24 | -$29.93 | -$41.88 | -$28.71 |
| Operating activities | ||||
| Depreciation | $3.68 | $3.16 | $1.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.86 | $5.34 | $5.96 | $5.23 |
| Total cash flows from operations | -$16.44 | -$26.97 | -$27.28 | -$18.86 |
| Investing activities | ||||
| Capital expenditures | -$4.95 | -$3.13 | -$10.43 | |
| Investments | ||||
| Total cash flows from investing | $18.66 | -$4.95 | -$3.13 | -$10.43 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.11 | $0.2 | $52.56 | $6.74 |
| Net borrowings | ||||
| Total cash flows from financing | $1.11 | $0.2 | $52.56 | $6.74 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $3.33 | -$31.72 | $22.14 | -$22.55 |
News
Fundamentals
| Market cap | $8.90M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 8.90M |
| Revenue | $5.40M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$9.70M |
| Revenue Q/Q | 647.66% |
| Revenue Y/Y | -40.47% |
| P/E ratio | -0.92 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 1.65 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$1.09 |
|---|---|
| ROA | -72.09% |
| ROE | N/A |
| Debt/Equity | 0.22 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.15 |
| Quick ratio | N/A |